Hyloris Pharmaceuticals (XBRU:HYL) Pretax Margin % : -943.47% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Hyloris Pharmaceuticals's Pre-Tax Income for the six months ended in Dec. 2023 was €-8.75 Mil. Hyloris Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was €0.93 Mil. Therefore, Hyloris Pharmaceuticals's pretax margin for the quarter that ended in Dec. 2023 was -943.47%.

The historical rank and industry rank for Hyloris Pharmaceuticals's Pretax Margin % or its related term are showing as below:

XBRU:HYL' s Pretax Margin % Range Over the Past 10 Years
Min: -6658.24 Med: -1776.06 Max: -364.41
Current: -736.94

XBRU:HYL's Pretax Margin % is ranked worse than
69.69% of 1013 companies
in the Biotechnology industry
Industry Median: -148.6 vs XBRU:HYL: -736.94

Hyloris Pharmaceuticals Pretax Margin % Historical Data

The historical data trend for Hyloris Pharmaceuticals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Pretax Margin % Chart

Hyloris Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pretax Margin %

Get a 7-Day Free Trial

-6,353.85

-4,082.86

-364.41

-1,322.33

-736.94

Hyloris Pharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Pretax Margin %	Get a 7-Day Free Trial							-134.72	-478.41	5,232.33	-571.90	-943.47

Competitive Comparison of Hyloris Pharmaceuticals's Pretax Margin %

For the Biotechnology subindustry, Hyloris Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyloris Pharmaceuticals's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's Pretax Margin % falls into.

Hyloris Pharmaceuticals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Hyloris Pharmaceuticals's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-15.38	/	2.087
	=	-736.94 %

Hyloris Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-8.746	/	0.927
	=	-943.47 %

Hyloris Pharmaceuticals (XBRU:HYL) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Hyloris Pharmaceuticals Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » Pretax Margin %

Comparable Companies

Traded in Other Exchanges

0AB6:UK 52U:Germany

Address

Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain with various other products in the pipeline. Its revenue is mainly generated in the United States.